Introduction {#s1}
============

Vitamin D is a prohormone synthesized by sun-exposure and dietary intake ([@B1]). Besides its role in bone integrity and calcium homeostasis ([@B2]), vitamin D status is also associated with cardiovascular morbidity and mortality ([@B3]--[@B6]). Vitamin D has a protective effect on endothelial function and vascular remodeling in experimental models ([@B7], [@B8]). One meta-analysis has shown that low vitamin D level is associated with 2.5-fold increase of the risk of ischemic stroke ([@B9]). However, the benefit of vitamin D supplementation in improving cardiovascular outcome remains controversial ([@B10]--[@B12]).

Several studies have suggested that low vitamin D is also associated with poor outcome in patients with acute ischemic stroke (AIS) ([@B13]--[@B17]). In these studies, logistic regression analysis alone was used to assess the relationship between low vitamin D status and prognosis of AIS patients. Logistic regression analysis should consider model complexity including interaction and model appropriateness using goodness of fit ([@B18]). Vitamin D is associated with several cardiovascular risk factors, including hypertension ([@B19]), insulin resistance ([@B20]), cerebral small vessel disease burden ([@B21]), stroke severity ([@B16], [@B17]), infarct volume ([@B22]), mood ([@B23]), and cognition ([@B24]) in previous studies. However, studies considering these interactions in logistic regression models are scarce.

Recently, machine learning (ML) has been found to be capable of accurately predicting prognosis in several disease categories, including cancer ([@B25]), cardiovascular disease ([@B26]), and psychiatric disorders ([@B27]). ML has advantage of being able to deal with large-size data and having several optimization technique, thus reducing the overfitting of training algorithms ([@B28]). In addition, several ML models such as random forest and extreme gradient boosting are tree-based feature selection ML algorithms that enable us to find non-linear relationship and interactions between independent variables more efficiently compared to logistic regression model ([@B29]). In this study on the association between vitamin D and stroke prognosis, we hypothesize that low vitamin D is associated with poor outcome in patients with AIS and that the predicting performance of extreme gradient boosting is superior to that of binary logistic regression for considering vitamin D with several risk factors.

Materials and Methods {#s2}
=====================

Study Population
----------------

The present study was a single-center retrospective study that screened all patients with AIS within 7 days of symptom onset using prospectively collected hospital registry. From August 2013 to October 2015, a total of 738 AIS patients with a positive diffusion-weighted lesion on brain MRI were selected for screening. We excluded patients with prior history of stroke (*n* = 243) because dietary intake or physical activity known to be associated with vitamin D intake and biosynthesis could be affected by premorbid neurological status. Additionally, patients without 3-month outcome capture (*n* = 85) and laboratory measures including admission serum 25-hydroxyvitamin D level (*n* = 82) were excluded.

Measurement of Serum 25-Hydroxyvitamin D Level
----------------------------------------------

Vitamin D status was determined by serum 25-hydroxyvitamin D concentration, a major circulating form with a long circulating half-life (\~3 weeks) ([@B30]). 25-hydroxyvitamin D level was measured within 24 h of admission using a radioimmunoassay kit (DiaSorin Liaison, Stillwater, MN, USA) with \<10% of inter-assay coefficient of variation. The assay was standardized against NIST Standard Reference Material 2972 (NIST, Gaithersburg, ME, USA) and certified by the Centers for Disease Control and Prevention Vitamin D Standardization Program. 25-hydroxyvitamin D deficiency was defined when its concentration was \<10 ng/mL following the criteria of Korean population study ([@B31]).

Covariates
----------

Definitions for vascular risk factors were based on our previous reports ([@B32]). Hypertension was defined if participants were taking antihypertensive medications or if their average sitting systolic blood pressure was 140/90 mmHg or more. Diabetes was defined if they were taking medical treatments for diabetes, if they had a fasting serum glucose level of 126 mg/dL or more, or if they had a non-fasting random serum glucose level of 200 mg/dL or more with corresponding symptoms of diabetes. Subjects were considered to have hyperlipidemia if they had a fasting total cholesterol level of 240 mg/dL or more or if they were being treated with a lipid-lowering agent. A current smoker was defined as a person smoking one or more cigarettes per day within the last 6 months. Stroke subtypes were classified as large artery atherosclerosis (LAA), small vessel occlusion (SVO), cardioembolism (CE), undetermined etiology (SUE), and other determined etiology (SOE) according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria ([@B33]). Laboratory parameters included serum level of fasting blood sugar, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, blood urea nitrogen, creatinine, and whole blood level of white blood cell count, hemoglobin, and platelet count.

Outcomes
--------

Primary outcome measure was 3-months poor functional outcome defined as a modified Rankin Scale (mRS) score of 3--6. Certified neurologists and nurses assessed the mRS score. Secondary outcome was F1 score of the prediction model (binary logistic regression vs. extreme gradient boosting) for AIS prognosis classification. F1 score is a measure of the model\'s accuracy. It represents harmonized mean of precision (positive predictive value) and recall (sensitivity) of the ML classifier.

Statistical Analysis
--------------------

Baseline characteristics according to tertiles of 25-hydroxyvitamin D were compared with analysis of variance or Kruskal Wallis test for continuous variables. For categorical variables, Pearson\'s χ^2^-test or Fisher\'s exact test was used. We performed univariate and multivariate logistic regression analyses for 3-months poor functional outcome (mRS 3--6) according to 25-hydroxyvitamin D status. All variables that were significant with *p* \< 0.10 in univariable analysis, age, and sex were entered into multivariable models. Two-sided *p* \< 0.05 was considered significant in multivariable analysis performed with R version 3.4.1 (the R Foundation for Statistical Computing).

Machine Learning Algorithm
--------------------------

We used the Extreme Gradient Boosting (XGBoost) R package that could perform regression and classification task well. XGBoost is an ML algorithm widely used in various Kaggle contests because it can perform non-linear prediction well, deal with missing data, and prove that computational speed is faster than other ML methods ([@B34]). As previously mentioned, we labeled patient\'s outcome as good (mRS: 0--2) or poor (mRS: 3--6). All participants\' dataset were randomly divided into 2 group: training (60% of 328 subjects) and testing (40%). Proportion of poor outcome in training and testing dataset was identically allocated using R cart package. Input features of this model were independent variables in the multivariate logistic regression model. Precise parameter tuning methods of XGBoost for preventing overfitting of this ML model are shown in [Supplemental Material](#s8){ref-type="supplementary-material"}. We calculated the probabilistic score of the prediction model of binary logistic regression and extreme gradient boosting algorithm, in which we set the probabilistic score of 0.5 or more to "poor outcome" (or test positive) and those \<0.5 to "good outcome." We presented the performance of these two classification tasks as precision, recall, accuracy, and F1 score. We compared model performance with area under the ROC curve (AUROC). Additionally, we also examined the performance of other machine learning algorithms such as support vector machines.

Results {#s3}
=======

Baseline Characteristics According to 25-Hydroxyvitamin D Tertile
-----------------------------------------------------------------

A total of 328 patients (mean age, 67.4 ± 13.2 years; male, 59.1%) were included in this study ([Table 1](#T1){ref-type="table"}). The mean (± standard deviation) and median \[interquartile range (IQR)\] of 25-hydroxyvitamin D were 11.5 ± 6.1 and 10.3 (7.1--14.7) ng/mL, respectively. The 25-hydroxyvitamin D tertile was inversely correlated with NIHSS score (*p* for Kruskal Wallis test = 0.029) and blood urea nitrogen level (*p* for one-way ANOVA = 0.007). It was negatively correlated with hemoglobin level (*p* for one-way ANOVA \< 0.001). Stroke subtype and cardiovascular risk factors such as hypertension, diabetes, smoking, or atrial fibrillation showed no significant associations with 25-hydroxyvitamin D tertile.

###### 

Baseline characteristic of participants according to 25-hydroxyvitamin D tertile.

                                   **Total**        **25-hydroxyvitamin D concentration**   ***p***                            
  -------------------------------- ---------------- --------------------------------------- ----------------- ---------------- ---------
  Age (±SD), years                 67.4 ± 13.2      69.5 ± 14.0                             66.2 ± 13.1       66.7 ± 12.4      0.138
  Male, %                          194 (59.1)       58 (53.2)                               65 (59.6)         71 (64.5)        0.231
  BMI, IQR, Kg/m^2^                24.0 ± 3.4       24.2 ± 4.4                              23.8 ± 2.7        23.9 ± 2.8       0.720
  Hypertension, %                  220 (67.1)       79 (72.5)                               75 (68.8)         66 (60.0)        0.130
  Diabetes, %                      104 (31.7)       42 (38.5)                               32 (29.4)         30 (27.3)        0.164
  Hyperlipidemia, %                116 (35.4)       42 (38.5)                               41 (37.6)         33 (30.0)        0.349
  Current smoking, %               138 (42.1)       41 (37.6)                               45 (41.3)         52 (47.3)        0.344
  Atrial fibrillation, %           65 (19.8)        20 (18.3)                               23 (21.1)         22 (20.0)        0.877
  TOAST classification                                                                                                         0.469
  LAA                              124 (37.8)       35 (32.1)                               46 (42.2)         43 (39.1)        
  SVO                              94 (28.7)        31 (28.4)                               29 (26.6)         34 (30.9)        
  CE                               65 (19.8)        22 (20.2)                               22 (20.2)         21 (19.1)        
  SOE and SUE                      45 (13.7)        21 (19.3)                               12 (11.0)         12 (10.9)        
  NIHSS score, mean ± SD           5.4 ± 6.0        6.6 ± 7.1                               5.5 ± 5.6         4.2 ± 5.0        0.012
  Median(IQR)                      3.0 (1.0--8.8)   3.0 (1.5--9.5)                          3.0 (1.5--11.0)   2.0 (1.0--5.3)   0.029
  IV thrombolysis                  44 (13.4)        13 (11.9)                               20 (18.3)         11 (10.0)        0.166
  Fasting blood glucose, mg/dL     125 ± 53         131 ± 62                                118 ± 39          124 ± 54         0.217
  Total cholesterol, mg/dL         181 ± 40         177 ± 47                                182 ± 42          185 ± 31         0.281
  TG, mg/dL                        121 ± 74         126 ± 82                                110 ± 58          125 ± 78         0.205
  HDL, mg/dL                       49 ± 16          47 ± 15                                 49 ± 16           51 ± 17          0.102
  LDL, mg/dL                       115 ± 37         111 ± 43                                116 ± 38          117 ± 29         0.377
  BUN, mg/dL                       16.9 ± 8.7       19.1 ± 10.8                             15.8 ± 8.5        15.9 ± 5.7       0.007
  Creatinine, mg/dL                0.9 ± 1.1        1.1 ± 1.3                               0.8 ± 0.4         0.9 ± 1.3        0.206
  eGFR, mL/min/1.73 m^2^           62.3 ± 84.9      69.2 ± 97.0                             52.5 ± 23.2       65.3 ± 107.8     0.313
  WBC count, × 10^3^ cells/mm^3^   8.2 ± 3.3        8.3 ± 3.0                               8.0 ± 2.4         8.3 ± 4.2        0.803
  Hemoglobin, g/dL                 13.6 ± 2.1       13.0 ± 2.4                              13.8 ± 1.9        14.1 ± 1.7       \<0.001
  Platelet count, × 10^3^/L        227 ± 77         231 ± 85                                235 ± 90          215 ± 50         0.146
  BPsystolic, mmHg                 148 ± 26         149 ± 26                                147 ± 27          148 ± 26         0.751
  BPdiastolic, mmHg                85 ± 16          85 ± 15                                 85 ± 16           85 ± 16          0.944

*BMI, body mass index; IQR, interquartile range; TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism; SOE, stroke of other determined etiology; SUE, stroke of undetermined etiology; NIHSS, National Institute of Health Stroke Scale; IV, intravenous; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; WBC, white blood cell; BP, blood pressure*.

25-Hydroxyvitamin D Level and Poor Outcome
------------------------------------------

Of 328 participants, proportions of AIS patients with poor 3-months outcome and 25-hydroxyvitamin D deficiency were 22.9 and 48.2%, respectively ([Table 2](#T2){ref-type="table"}). Patients with 25-hydroxyvitamin D deficiency tended to have higher mRS score compared to those without such deficiency (p for χ^2^ trend = 0.026, [Figure 1](#F1){ref-type="fig"}). Poor outcome at 3-months was positively associated with age, female gender, stroke severity, blood urea nitrogen, and white blood cell count. Hemoglobin level and 25-hydroxyvitamin D deficiency were inversely associated with poor outcome in patients with AIS. In univariate analysis, 25-hydroxyvitamin D deficiency was a predictor for poor 3-months outcome \[OR (odds ratio), 1.86; CI (confidence interval), 1.10--3.14; *p* = 0.021\]. Although age, sex, stroke severity, stroke subtype, intravenous thrombolysis, blood urea nitrogen, white blood cell count, and hemoglobin were adjusted in the multivariate logistic regression model, 25-hydroxyvitamin D deficiency was a significant predictor for 3-months poor outcome (OR, 3.21; CI, 1.22--8.48; *p* = 0.019, [Table 3](#T3){ref-type="table"}).

###### 

Differences of demographic and clinical characteristics between good and poor outcome groups of patients with acute ischemic stroke.

                                      **Poor (*n* = 75)**   **Good (*n* = 253)**   **Total (*n* = 328)**   ***p***
  ----------------------------------- --------------------- ---------------------- ----------------------- ---------
  Age, years                          72.6 ± 14.3           65.9 ± 12.5            67.4 ± 13.2             \<0.001
  Male, %                             37 (49.3)             157 (62.1)             194 (59.1)              0.049
  BMI, Kg/m^2^                        24.2 ± 5.1            23.9 ± 2.7             24.0 ± 3.4              0.628
  Hypertension, %                     54 (72.0)             166 (65.6)             220 (67.1)              0.301
  Diabetes, %                         25 (33.3)             79 (31.2)              104 (31.7)              0.730
  Hyperlipidemia, %                   29 (38.7)             87 (34.4)              116 (35.4)              0.496
  Current smoking, %                  27 (36.0)             111 (43.9)             138 (42.1)              0.225
  Atrial fibrillation, %              19 (25.3)             46 (18.2)              65 (19.8)               0.172
  TOAST classification                                                                                     0.329
  LAA                                 27 (36.0)             97 (38.3)              124 (37.8)              
  SVO                                 17 (22.7)             77 (30.4)              94 (28.7)               
  CE                                  17 (22.7)             48 (19.0)              65 (19.8)               
  SOE and SUE                         14 (18.7)             31 (12.3)              45 (13.7)               
  NIHSS, mean ± SD                    10.2 ± 7.0            4.0 ± 4.9              5.4 ± 6.0               \<0.001
  NIHSS, median (IQR)                 9 (4-15)              2 (1-5)                3.0 (1.0--8.8)          \<0.001
  IV thrombolysis                     15 (20.0)             29 (11.5)              44 (13.4)               0.057
  Fasting blood glucose, mg/dL        131 ± 57              123 ± 52               125 ± 53                0.240
  Total cholesterol, mg/dL            187 ± 47              180 ± 38               181 ± 40                0.195
  TG, mg/dL                           110 ± 82              124 ± 71               121 ± 74                0.154
  HDL, mg/dL                          52 ± 14               48 ± 16                49 ± 16                 0.120
  LDL, mg/dL                          119 ± 45              113 ± 35               115 ± 37                0.252
  BUN, mg/dL                          18.9 ± 8.7            16.3 ± 8.6             16.9 ± 8.7              0.026
  Creatinine, mg/dL                   0.9 ± 0.4             1.0 ± 1.2              0.9 ± 1.1               0.456
  WBC count, × 10^3^ cells/mm^3^      8.9 ± 3.2             8.0 ± 3.3              8.2 ± 3.3               0.032
  Hemoglobin, g/dL                    13.2 ± 2.4            13.8 ± 2.0             13.6 ± 2.1              0.040
  Platelet count, × 10^3^/L           234 ± 92              225 ± 72               227 ± 77                0.378
  BPsystolic, mmHg                    149 ± 26              147 ± 26               148 ± 26                0.613
  BPdiastolic, mmHg                   83 ± 15               86 ± 16                85 ± 16                 0.288
  25-hydroxyvitamin D deficiency, %   45 (60.0)             113 (44.7)             158 (48.2)              0.020

*BMI, body mass index; TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism; SOE, stroke of other determined etiology; SUE, stroke of undetermined etiology; NIHSS, National Institute of Health Stroke Scale; IQR, interquartile range; IV, intravenous; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; WBC, white blood cell; BP, blood pressure*.

![Distribution of 3-month modified Rankin Scale score according to 25-hydroxyvitamin D deficiency status.](fneur-11-00037-g0001){#F1}

###### 

Binary logistic regression analysis of predictors for poor functional outcome (mRS 3-6) at 3 months.

                                    **OR (95% CI)**     ***p***
  --------------------------------- ------------------- ---------
  25(OH)D deficiency (\<10 ng/mL)   1.86 (1.10--3.14)   0.021
  Model 1                           1.74 (1.01--2.97)   0.044
  Model 2                           3.01 (1.16--7.84)   0.024
  Model 3                           3.18 (1.21--8.36)   0.019
  Model 4                           3.21 (1.22--8.48)   0.019

*mRS, modified Rankin Scale; OR, odds ratio; CI, confidence interval; 25(OH)D, 25-hydroxyvitamin D. Model 1 was adjusted for age and sex. Model 2 included variables in model 1 plus NIHSS and NIHSS^\*^25-hydroxyvitamin D deficiency interaction term. Model 3 included variables in model 2 plus stroke subtype (TOAST classification) and intravenous thrombolysis. Model 4 included variables in model 3 plus blood urea nitrogen, white blood cell count, and hemoglobin*.

Comparison of Logistic Regression and the Other Machine Learning Classifier
---------------------------------------------------------------------------

We used extreme gradient boosting ML algorithm to classify and predict factors associated with poor 3-months outcome of AIS. [Figure 2](#F2){ref-type="fig"} shows factors affecting this binary classification weighed by XGBoost algorithm. NIHSS (feature importance, 32.8%) score was the top predictive factor affecting XGBoost classification, followed by age (16.0%) and 25-hydroxyvitamin D level (12.5%) in the training dataset. [Table 4](#T4){ref-type="table"} shows result of classification performance of binary logistic regression and extreme gradient boosting to predict 3-months poor outcome. Overall prediction performances including precision, recall, accuracy, and F1 score were higher in extreme gradient boosting model compared to those in the binary logistic regression model. [Figure 3](#F3){ref-type="fig"} shows performances of these two classifiers with AUROC curve analysis for the test dataset (total 131 subjects). The XGBoost\'s performance was higher than those of logistic regression in classifying prognosis of patients with AIS, but statistical significance was not achieved (AUROC, 0.805 vs. 0.746, *p*-value = 0.11). We also examined the performance of the support vector machine for the binary prediction of poor outcome, and overall procedures of the support vector machine was presented in the [Supplemental Material](#s8){ref-type="supplementary-material"}.

![Variable importance plot for XGBoost. NIHSS, National Institute of Health Stroke Scale; 25-OH D, 25-hydroxyvitamin D, WBC, white blood cell; BUN, blood urea nitrogen; TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAA, large artery atherosclerosis; d2-3, 2nd and 3rd dummy variable; IV, intravenous. X-axis represents variable importance in the extreme gradient boosting prediction.](fneur-11-00037-g0002){#F2}

###### 

Results of classification performance of binary logistic regression and extreme gradient boosting to predict 3-month poor outcome of AIS patients in the test data.

        **TP**   **FP**   **FN**   **TN**   **Total**   **Recall**   **Specificity**   **Precision**   **NPV**   **Accuracy**   **F1 score**
  ----- -------- -------- -------- -------- ----------- ------------ ----------------- --------------- --------- -------------- --------------
  BLR   10       11       15       95       131         40.0         89.6              47.6            86.4      80.2           43.5
  XGB   12       10       13       96       131         48.0         90.6              54.5            88.1      82.4           51.1

*TP, true positive; FP, false positive; FN, false negative; TN, true negative; NPV, negative predictive value; BLR, binary logistic regression; XGB, extreme gradient boosting*.

![Receiver operating characteristic curve of binary logistic regression and extreme gradient boosting algorithm. BLR, binary logistic regression; XGB, extreme gradient boosting.](fneur-11-00037-g0003){#F3}

Discussion {#s4}
==========

Our study ascertained that low 25-hydroxyvitamin D status in stroke patients was highly prevalent even at the time of admission of AIS patients and that 25-hydroxyvitamin D status was a significant predictor for poor outcome after adjusting multiple variables in logistic regression model. Additionally, serum 25-hydroxyvitamin D level was also associated with a poor outcome in the XGBoost ML model that considered multiple interactions.

Are there possible causal relationship between vitamin D deficiency and stroke prognosis? First, it has been shown that endothelial dysfunction has an important role in atherosclerosis and stroke development ([@B35], [@B36]). Markers for endothelial dysfunction are associated with stroke lesion volume or clinical outcome ([@B37]). Witham et al. have reported that high dose vitamin D supplementation for 16 weeks can increase flow mediated dilatation in patients with stroke ([@B38]) which is one of well-known predictors for the cardiovascular outcome ([@B39]). These could explain a possible link between vitamin D status and stroke outcome. Second, low vitamin D status is closely related to "general health status" which could reflect individual\'s physical activity or dietary intake. On the contrary, vitamin D status can predict physical performance in an aged populations ([@B40]). Krarup et al. have reported that pre-stroke physical activity is associated with severity and long-term outcome from first-ever ischemic stroke ([@B41]). In this regards, low 25-hydroxyvitamin D could be a result of poor general health or increased frailty in these stroke population. New interventional studies on 25-hydroxyvitamin D supplementation in AIS patients with low vitamin D status are needed to improve our understanding of role of 25-hydroxyvitamin D in cardiovascular disease.

We observed that 25-hydroxyvitamin D levels were extremely low in our stroke population compared to the normal Korean population ([@B31]). If so, how can we explain these high prevalence of 25-hydroxyvitamin D deficiency or insufficiency in stroke participants? First, the prevalence of 25-hydroxyvitamin D deficiency has been gradually increasing as more people are living in a modernized and indoor place in which sun light exposure is insufficient to produce vitamin D biosynthesis. Analysis of national health surveys in US could support this hypothesis ([@B42]). Second, relatively high prevalence of vitamin D deficiency in stroke patients has been reported in other cohorts ([@B43], [@B44]). In these studies, mean level of 25-hydroxyvitamin D concentration ranged from 13.7 to 14.2 ng/mL, comparable to that of our study. Unquestionably, prevalence of vitamin D deficiency is a pandemic phenomenon. It has markedly increased irrespective of age, sex, ethnicity, types of concurrent comorbidity, or socioeconomic state.

Despite of these positive correlation between 25-hydroxyvitamin D deficiency and various cardiovascular outcomes, there have been few evidence of randomized controlled trials whether vitamin D supplementation has a positive effect on the cardiovascular outcome ([@B45]). These discrepancies could be partly explained by various factors such as supplemental dosage of vitamin D, ethnical and environmental factors for the study participants, study design, and outcome in each trials. It\'s too early to conclude that vitamin D deficiency is as salient predictor for cardiovascular disease. Therefore, future trial are necessary to consider these differences and the exact causal pathways of vitamin D metabolism. We used logistic regression and XGBoost ML algorithm to predict stroke outcome in this study. Logistic regression is the most popular multivariate statistical method in medical science. Using logistic regression, we can quantitatively estimate the relationship between two variables of interest through an index called "odds ratio." However, it is impossible to consider all interactions among variables in logistic regression because there might be a variety of combinations of interactions between variables in the real world. Results of XGBoost ML algorithm showed that, in addition to important predictors such as stroke and stroke severity, factors such as 25-hydroxyvitamin D, white blood cell count, and hemoglobin were also important factors predicting prognosis of stroke patients. We could suggest that 25-hydroxyvitamin D is associated with a variety of factors affecting stroke prognosis such as stroke severity, age, several laboratory parameters, stroke subtype, and gender and that XGBoost ML algorithm is useful for dealing with multiple interactions between independent predictors in binary classification of stroke prognosis. In addition, XGBoost algorithm can analyze large size data with a high computational speed. In this era, medical data are becoming so vast that it becomes hard to analyze. An ML approach can be an expeditious and efficient way to analyze such big data.

Our study has several limitations. First, our study was a single center retrospective case control study, although measurement of 25-hydroxyvitamin D level and 3-months clinical outcome capture were prospectively collected. Therefore, our results could not presume a causal relationship of vitamin D and stroke severity. In addition, they could not be generalizable to entire ischemic stroke patients or other ethnicities. Second, although pre-stroke physical activity and dietary intake were significant confounders in assessment with vitamin D level and stoke severity, we could not assess these variables in our model. However, some strengths of our study could reinforce the relationship between vitamin D status and stroke outcome. First, we excluded patients with prior history of stroke to minimize the effect of physical activity and dietary intake. Second, analysis of vitamin D and stroke outcome was adjusted for clinically important variables with a multivariate logistic model. Lastly, interactions between all independent variables were statistically considered by means of an ensemble ML mechanism called extreme gradient boosting.

In conclusion, 25-hydroxyvitamin D level is associated with 3-months poor outcome in patients with AIS. In addition, extreme gradient boosting ML algorithm could reveal the association of stroke prognosis with 25-hydroxyvitamin D level which might have certain interactions with other predictors.
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